Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 30Carcinoma, Non-Small-Cell Lung 14Lung Neoplasms 9Neoplasm Metastasis 3Neoplasms 2Hodgkin Disease 2Adenocarcinoma of Lung 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thoracic Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Pancreatic Neoplasms 1Mesothelioma 1Malignant Solid Tumour 1Lymphoma, T-Cell, Peripheral 1Lymphoma 1Lung Diseases 1Breast Neoplasms, Male 1Advanced Non-Small Cell Lung Cancer 1Adenocarcinoma, Bronchiolo-Alveolar 1

Interventions

Pemetrexed 5Carboplatin 5Paclitaxel 3osimertinib 2Gemcitabine 2pralsetinib 1pembrolizumab 1patritumab 1napabucasin 1atezolizumab 1alectinib 1Vinorelbine 1Patient Reported Outcome Measures 1Nivolumab 1Metformin 1Indocyanine Green 1Erlotinib Hydrochloride 1Cisplatin 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Thoracic Neoplasms × Vinorelbine × Clear all
NCT05583188 2024-07-19

VIGOR

Galvanize Therapeutics, Inc.

Phase 4 Terminated
5 enrolled
Thoracic

Lung Diseases, Lung Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡